MedTrace Logo

Effects of a High EPA Multinutrient Supplement on Negative Affect in Young Adults.

NCT04844034 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2023-06-01

No results posted yet for this study

Summary

This is a 12-week-long, randomised, double-blind, placebo-controlled trial exploring the efficacy of a high-EPA multinutrient supplement in the management of sub-clinical anxiety and depression. The investigators focus on young and healthy, adult university students, who may otherwise not be eligible for pharmacological or cognitive behavioural therapy interventions.

Conditions

Interventions

DIETARY_SUPPLEMENT

High-EPA multinutrient supplement.

Three capsules with the largest meal of the day providing: * 1,125 mg EPA * 441 mg DHA * 330 mg Magnesium * 7.5 mg a-tocopherol

OTHER

Placebo

Three capsules with the largest meal of the day providing: * 3,060 mg sunflower seed oil * 60 mg lecithin * 300 mg glyceryl monostearate * 465 mg EPA/DHA (18%/12% respectively for blinding)

Sponsors & Collaborators

  • University of Roehampton

    lead OTHER

Principal Investigators

  • Leigh Gibson, PhD · University of Roehampton

  • Simon Dyall, PhD · University of Roehampton

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-19
Primary Completion
2023-10-31
Completion
2023-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04844034 on ClinicalTrials.gov